instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
What was the outcome of reaction 'Amylase increased'? | Intrabiliary and abdominal rupture of hepatic hydatid cyst leading to biliary obstruction, cholangitis, pancreatitis, peritonitis and septicemia: a case report.
BACKGROUND
Hydatid cysts are fluid-filled sacs containing immature forms of parastic tapeworms of the genus Echinococcus. The most prevalent and serious compli... | Recovering | ReactionOutcome | CC BY | 34049575 | 20,143,424 | 2021-05-28 |
What was the outcome of reaction 'Aspartate aminotransferase increased'? | Intrabiliary and abdominal rupture of hepatic hydatid cyst leading to biliary obstruction, cholangitis, pancreatitis, peritonitis and septicemia: a case report.
BACKGROUND
Hydatid cysts are fluid-filled sacs containing immature forms of parastic tapeworms of the genus Echinococcus. The most prevalent and serious compli... | Recovered | ReactionOutcome | CC BY | 34049575 | 19,443,617 | 2021-05-28 |
What was the outcome of reaction 'Biliary obstruction'? | Intrabiliary and abdominal rupture of hepatic hydatid cyst leading to biliary obstruction, cholangitis, pancreatitis, peritonitis and septicemia: a case report.
BACKGROUND
Hydatid cysts are fluid-filled sacs containing immature forms of parastic tapeworms of the genus Echinococcus. The most prevalent and serious compli... | Recovered | ReactionOutcome | CC BY | 34049575 | 19,443,617 | 2021-05-28 |
What was the outcome of reaction 'Cholangitis'? | Intrabiliary and abdominal rupture of hepatic hydatid cyst leading to biliary obstruction, cholangitis, pancreatitis, peritonitis and septicemia: a case report.
BACKGROUND
Hydatid cysts are fluid-filled sacs containing immature forms of parastic tapeworms of the genus Echinococcus. The most prevalent and serious compli... | Recovered | ReactionOutcome | CC BY | 34049575 | 19,443,617 | 2021-05-28 |
What was the outcome of reaction 'Decreased appetite'? | Intrabiliary and abdominal rupture of hepatic hydatid cyst leading to biliary obstruction, cholangitis, pancreatitis, peritonitis and septicemia: a case report.
BACKGROUND
Hydatid cysts are fluid-filled sacs containing immature forms of parastic tapeworms of the genus Echinococcus. The most prevalent and serious compli... | Recovered | ReactionOutcome | CC BY | 34049575 | 19,443,617 | 2021-05-28 |
What was the outcome of reaction 'Fatigue'? | Intrabiliary and abdominal rupture of hepatic hydatid cyst leading to biliary obstruction, cholangitis, pancreatitis, peritonitis and septicemia: a case report.
BACKGROUND
Hydatid cysts are fluid-filled sacs containing immature forms of parastic tapeworms of the genus Echinococcus. The most prevalent and serious compli... | Recovered | ReactionOutcome | CC BY | 34049575 | 19,443,617 | 2021-05-28 |
What was the outcome of reaction 'Hepatic cyst ruptured'? | Intrabiliary and abdominal rupture of hepatic hydatid cyst leading to biliary obstruction, cholangitis, pancreatitis, peritonitis and septicemia: a case report.
BACKGROUND
Hydatid cysts are fluid-filled sacs containing immature forms of parastic tapeworms of the genus Echinococcus. The most prevalent and serious compli... | Recovered | ReactionOutcome | CC BY | 34049575 | 19,443,617 | 2021-05-28 |
What was the outcome of reaction 'Illness'? | Intrabiliary and abdominal rupture of hepatic hydatid cyst leading to biliary obstruction, cholangitis, pancreatitis, peritonitis and septicemia: a case report.
BACKGROUND
Hydatid cysts are fluid-filled sacs containing immature forms of parastic tapeworms of the genus Echinococcus. The most prevalent and serious compli... | Recovered | ReactionOutcome | CC BY | 34049575 | 19,443,617 | 2021-05-28 |
What was the outcome of reaction 'Jaundice'? | Intrabiliary and abdominal rupture of hepatic hydatid cyst leading to biliary obstruction, cholangitis, pancreatitis, peritonitis and septicemia: a case report.
BACKGROUND
Hydatid cysts are fluid-filled sacs containing immature forms of parastic tapeworms of the genus Echinococcus. The most prevalent and serious compli... | Recovered | ReactionOutcome | CC BY | 34049575 | 19,443,617 | 2021-05-28 |
What was the outcome of reaction 'Lipase increased'? | Intrabiliary and abdominal rupture of hepatic hydatid cyst leading to biliary obstruction, cholangitis, pancreatitis, peritonitis and septicemia: a case report.
BACKGROUND
Hydatid cysts are fluid-filled sacs containing immature forms of parastic tapeworms of the genus Echinococcus. The most prevalent and serious compli... | Recovering | ReactionOutcome | CC BY | 34049575 | 20,143,424 | 2021-05-28 |
What was the outcome of reaction 'Pancreatitis'? | Intrabiliary and abdominal rupture of hepatic hydatid cyst leading to biliary obstruction, cholangitis, pancreatitis, peritonitis and septicemia: a case report.
BACKGROUND
Hydatid cysts are fluid-filled sacs containing immature forms of parastic tapeworms of the genus Echinococcus. The most prevalent and serious compli... | Recovered | ReactionOutcome | CC BY | 34049575 | 19,443,617 | 2021-05-28 |
What was the outcome of reaction 'Peritonitis'? | Intrabiliary and abdominal rupture of hepatic hydatid cyst leading to biliary obstruction, cholangitis, pancreatitis, peritonitis and septicemia: a case report.
BACKGROUND
Hydatid cysts are fluid-filled sacs containing immature forms of parastic tapeworms of the genus Echinococcus. The most prevalent and serious compli... | Recovered | ReactionOutcome | CC BY | 34049575 | 19,443,617 | 2021-05-28 |
What was the outcome of reaction 'Pyrexia'? | Intrabiliary and abdominal rupture of hepatic hydatid cyst leading to biliary obstruction, cholangitis, pancreatitis, peritonitis and septicemia: a case report.
BACKGROUND
Hydatid cysts are fluid-filled sacs containing immature forms of parastic tapeworms of the genus Echinococcus. The most prevalent and serious compli... | Recovered | ReactionOutcome | CC BY | 34049575 | 19,443,617 | 2021-05-28 |
What was the outcome of reaction 'Sepsis'? | Intrabiliary and abdominal rupture of hepatic hydatid cyst leading to biliary obstruction, cholangitis, pancreatitis, peritonitis and septicemia: a case report.
BACKGROUND
Hydatid cysts are fluid-filled sacs containing immature forms of parastic tapeworms of the genus Echinococcus. The most prevalent and serious compli... | Recovered | ReactionOutcome | CC BY | 34049575 | 19,443,617 | 2021-05-28 |
What was the outcome of reaction 'Toxicity to various agents'? | Intrabiliary and abdominal rupture of hepatic hydatid cyst leading to biliary obstruction, cholangitis, pancreatitis, peritonitis and septicemia: a case report.
BACKGROUND
Hydatid cysts are fluid-filled sacs containing immature forms of parastic tapeworms of the genus Echinococcus. The most prevalent and serious compli... | Recovered | ReactionOutcome | CC BY | 34049575 | 19,443,617 | 2021-05-28 |
What was the outcome of reaction 'Vomiting'? | Intrabiliary and abdominal rupture of hepatic hydatid cyst leading to biliary obstruction, cholangitis, pancreatitis, peritonitis and septicemia: a case report.
BACKGROUND
Hydatid cysts are fluid-filled sacs containing immature forms of parastic tapeworms of the genus Echinococcus. The most prevalent and serious compli... | Recovered | ReactionOutcome | CC BY | 34049575 | 19,443,617 | 2021-05-28 |
What was the outcome of reaction 'White blood cell count increased'? | Intrabiliary and abdominal rupture of hepatic hydatid cyst leading to biliary obstruction, cholangitis, pancreatitis, peritonitis and septicemia: a case report.
BACKGROUND
Hydatid cysts are fluid-filled sacs containing immature forms of parastic tapeworms of the genus Echinococcus. The most prevalent and serious compli... | Recovering | ReactionOutcome | CC BY | 34049575 | 20,143,424 | 2021-05-28 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Infection'. | Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT.
There is no information on the impact of donor type in allogeneic hem... | BUSULFAN, CYCLOPHOSPHAMIDE, CYCLOSPORINE, METHOTREXATE, MYCOPHENOLATE MOFETIL, SIROLIMUS | DrugsGivenReaction | CC BY | 34049582 | 20,247,167 | 2021-05-28 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metastasis'. | Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT.
There is no information on the impact of donor type in allogeneic hem... | BUSULFAN, CYCLOPHOSPHAMIDE, CYCLOSPORINE, METHOTREXATE, MYCOPHENOLATE MOFETIL, SIROLIMUS | DrugsGivenReaction | CC BY | 34049582 | 20,247,167 | 2021-05-28 |
What was the outcome of reaction 'Infection'? | Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT.
There is no information on the impact of donor type in allogeneic hem... | Fatal | ReactionOutcome | CC BY | 34049582 | 20,247,167 | 2021-05-28 |
What was the outcome of reaction 'Metastasis'? | Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT.
There is no information on the impact of donor type in allogeneic hem... | Fatal | ReactionOutcome | CC BY | 34049582 | 20,247,167 | 2021-05-28 |
What was the dosage of drug 'HYDROCHLOROTHIAZIDE'? | Aetiology, course and treatment of acute tubulointerstitial nephritis in paediatric patients: a cross-sectional web-based survey.
Acute tubulointerstitial nephritis (TIN) is a significant cause of acute renal failure in paediatric and adult patients. There are no large paediatric series focusing on the aetiology, treat... | UNK UNK, UNKNOWN | DrugDosageText | CC BY-NC | 34049919 | 19,911,332 | 2021-05-28 |
What was the outcome of reaction 'Tubulointerstitial nephritis'? | Aetiology, course and treatment of acute tubulointerstitial nephritis in paediatric patients: a cross-sectional web-based survey.
Acute tubulointerstitial nephritis (TIN) is a significant cause of acute renal failure in paediatric and adult patients. There are no large paediatric series focusing on the aetiology, treat... | Recovering | ReactionOutcome | CC BY-NC | 34049919 | 19,939,054 | 2021-05-28 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug interaction'. | T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab.
Many adverse reactions associated with immune checkpoint inhibitor (ICI) treatments are immunologically driven and may necessitate discontinuation of the ICI. Herein, we present a patient who ... | ATEZOLIZUMAB, DIATRIZOATE SODIUM | DrugsGivenReaction | CC BY | 34049931 | 19,386,198 | 2021-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Stevens-Johnson syndrome'. | T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab.
Many adverse reactions associated with immune checkpoint inhibitor (ICI) treatments are immunologically driven and may necessitate discontinuation of the ICI. Herein, we present a patient who ... | ATEZOLIZUMAB, DIATRIZOATE SODIUM | DrugsGivenReaction | CC BY | 34049931 | 19,386,198 | 2021-05 |
What was the administration route of drug 'ATEZOLIZUMAB'? | T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab.
Many adverse reactions associated with immune checkpoint inhibitor (ICI) treatments are immunologically driven and may necessitate discontinuation of the ICI. Herein, we present a patient who ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34049931 | 19,386,198 | 2021-05 |
What was the administration route of drug 'DIATRIZOATE SODIUM'? | T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab.
Many adverse reactions associated with immune checkpoint inhibitor (ICI) treatments are immunologically driven and may necessitate discontinuation of the ICI. Herein, we present a patient who ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34049931 | 19,386,198 | 2021-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Adverse event'. | Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
Part B of this phase 1b study (ClinicalTrials.gov number, NCT02283775) evaluated safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibo... | ACETAMINOPHEN, DEXAMETHASONE, DIPHENHYDRAMINE, ISATUXIMAB, POMALIDOMIDE, RANITIDINE | DrugsGivenReaction | CC BY | 34050260 | 19,406,886 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Flushing'. | Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
Part B of this phase 1b study (ClinicalTrials.gov number, NCT02283775) evaluated safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibo... | ACETAMINOPHEN, DEXAMETHASONE, DIPHENHYDRAMINE, ISATUXIMAB, POMALIDOMIDE, RANITIDINE | DrugsGivenReaction | CC BY | 34050260 | 19,401,816 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gait disturbance'. | Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
Part B of this phase 1b study (ClinicalTrials.gov number, NCT02283775) evaluated safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibo... | ACETAMINOPHEN, DEXAMETHASONE, DIPHENHYDRAMINE, ISATUXIMAB, POMALIDOMIDE, RANITIDINE | DrugsGivenReaction | CC BY | 34050260 | 19,401,816 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Tremor'. | Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
Part B of this phase 1b study (ClinicalTrials.gov number, NCT02283775) evaluated safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibo... | ACETAMINOPHEN, DEXAMETHASONE, DIPHENHYDRAMINE, ISATUXIMAB, POMALIDOMIDE, RANITIDINE | DrugsGivenReaction | CC BY | 34050260 | 19,401,816 | 2021-12 |
What was the administration route of drug 'ACETAMINOPHEN'? | Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
Part B of this phase 1b study (ClinicalTrials.gov number, NCT02283775) evaluated safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibo... | Oral | DrugAdministrationRoute | CC BY | 34050260 | 19,401,816 | 2021-12 |
What was the administration route of drug 'DEXAMETHASONE'? | Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
Part B of this phase 1b study (ClinicalTrials.gov number, NCT02283775) evaluated safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibo... | Oral | DrugAdministrationRoute | CC BY | 34050260 | 19,406,886 | 2021-12 |
What was the administration route of drug 'DIPHENHYDRAMINE'? | Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
Part B of this phase 1b study (ClinicalTrials.gov number, NCT02283775) evaluated safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibo... | Intravenous drip | DrugAdministrationRoute | CC BY | 34050260 | 19,401,816 | 2021-12 |
What was the administration route of drug 'ISATUXIMAB'? | Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
Part B of this phase 1b study (ClinicalTrials.gov number, NCT02283775) evaluated safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibo... | Oral | DrugAdministrationRoute | CC BY | 34050260 | 19,406,886 | 2021-12 |
What was the administration route of drug 'POMALIDOMIDE'? | Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
Part B of this phase 1b study (ClinicalTrials.gov number, NCT02283775) evaluated safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibo... | Oral | DrugAdministrationRoute | CC BY | 34050260 | 19,401,816 | 2021-12 |
What was the administration route of drug 'RANITIDINE'? | Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
Part B of this phase 1b study (ClinicalTrials.gov number, NCT02283775) evaluated safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibo... | Intravenous drip | DrugAdministrationRoute | CC BY | 34050260 | 19,401,816 | 2021-12 |
What was the dosage of drug 'ACETAMINOPHEN'? | Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
Part B of this phase 1b study (ClinicalTrials.gov number, NCT02283775) evaluated safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibo... | 650?1000 MG | DrugDosageText | CC BY | 34050260 | 19,401,816 | 2021-12 |
What was the dosage of drug 'DIPHENHYDRAMINE'? | Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
Part B of this phase 1b study (ClinicalTrials.gov number, NCT02283775) evaluated safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibo... | 25?50 MG | DrugDosageText | CC BY | 34050260 | 19,401,816 | 2021-12 |
What was the dosage of drug 'ISATUXIMAB'? | Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
Part B of this phase 1b study (ClinicalTrials.gov number, NCT02283775) evaluated safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibo... | 10 MILLIGRAM/KILOGRAM | DrugDosageText | CC BY | 34050260 | 19,406,886 | 2021-12 |
What was the dosage of drug 'RANITIDINE'? | Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
Part B of this phase 1b study (ClinicalTrials.gov number, NCT02283775) evaluated safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibo... | 50 mg (milligrams). | DrugDosage | CC BY | 34050260 | 19,401,816 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?
Givosiran is a novel approach to treat patients with acute intermittent porphyrias (AIP) by silencing of ∂-ALA-synthase 1, the first enzyme of heme biosynthesis in the liver. We included two patients in the Envision... | OLANZAPINE | DrugsGivenReaction | CC BY | 34050373 | 19,685,610 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pancreatitis necrotising'. | Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?
Givosiran is a novel approach to treat patients with acute intermittent porphyrias (AIP) by silencing of ∂-ALA-synthase 1, the first enzyme of heme biosynthesis in the liver. We included two patients in the Envision... | OLANZAPINE | DrugsGivenReaction | CC BY | 34050373 | 19,685,610 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pseudocyst'. | Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?
Givosiran is a novel approach to treat patients with acute intermittent porphyrias (AIP) by silencing of ∂-ALA-synthase 1, the first enzyme of heme biosynthesis in the liver. We included two patients in the Envision... | OLANZAPINE | DrugsGivenReaction | CC BY | 34050373 | 19,685,610 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Acute myocardial infarction'. | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | ABIRATERONE ACETATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34050660 | 19,980,013 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Alanine aminotransferase increased'. | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | ABIRATERONE ACETATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34050660 | 19,407,420 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Angina pectoris'. | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | ABIRATERONE ACETATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34050660 | 19,407,420 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Aspartate aminotransferase increased'. | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | ABIRATERONE ACETATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34050660 | 19,407,420 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Bradycardia'. | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | ABIRATERONE ACETATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34050660 | 19,407,420 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Chest pain'. | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | ABIRATERONE ACETATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34050660 | 19,407,420 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Decreased appetite'. | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | ABIRATERONE ACETATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34050660 | 19,407,420 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug-induced liver injury'. | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | ABIRATERONE ACETATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34050660 | 19,407,420 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Fluid retention'. | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | ABIRATERONE ACETATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34050660 | 19,407,420 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatic enzyme increased'. | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | ABIRATERONE ACETATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34050660 | 19,407,420 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatic function abnormal'. | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | ABIRATERONE ACETATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34050660 | 19,979,992 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatotoxicity'. | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | ABIRATERONE ACETATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34050660 | 19,407,420 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypertension'. | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | ABIRATERONE ACETATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34050660 | 19,407,420 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypoaesthesia'. | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | ABIRATERONE ACETATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34050660 | 19,407,420 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypokalaemia'. | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | ABIRATERONE ACETATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34050660 | 19,407,420 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Liver disorder'. | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | ABIRATERONE ACETATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34050660 | 19,407,420 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Loss of consciousness'. | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | ABIRATERONE ACETATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34050660 | 19,407,420 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Malaise'. | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | ABIRATERONE ACETATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34050660 | 19,407,420 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Myocardial infarction'. | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | ABIRATERONE ACETATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34050660 | 19,407,422 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nausea'. | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | ABIRATERONE ACETATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34050660 | 19,407,420 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Oedema peripheral'. | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | ABIRATERONE ACETATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34050660 | 19,407,420 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Ventricular tachycardia'. | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | ABIRATERONE ACETATE, PREDNISOLONE | DrugsGivenReaction | CC BY | 34050660 | 19,407,420 | 2021-08-30 |
What was the administration route of drug 'ABIRATERONE ACETATE'? | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | Oral | DrugAdministrationRoute | CC BY | 34050660 | 19,979,992 | 2021-08-30 |
What was the outcome of reaction 'Acute myocardial infarction'? | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | Fatal | ReactionOutcome | CC BY | 34050660 | 19,980,013 | 2021-08-30 |
What was the outcome of reaction 'Hepatic function abnormal'? | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | Recovered | ReactionOutcome | CC BY | 34050660 | 19,979,992 | 2021-08-30 |
What was the outcome of reaction 'Hepatotoxicity'? | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | Recovered | ReactionOutcome | CC BY | 34050660 | 19,407,420 | 2021-08-30 |
What was the outcome of reaction 'Hypoaesthesia'? | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | Not recovered | ReactionOutcome | CC BY | 34050660 | 19,407,420 | 2021-08-30 |
What was the outcome of reaction 'Hypokalaemia'? | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | Fatal | ReactionOutcome | CC BY | 34050660 | 19,979,991 | 2021-08-30 |
What was the outcome of reaction 'Myocardial infarction'? | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | Fatal | ReactionOutcome | CC BY | 34050660 | 19,407,422 | 2021-08-30 |
What was the outcome of reaction 'Nausea'? | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study.
BACKGROUND
Abiraterone acetate plus prednisolone is approved to treat patients with castration-resistant prostate cancer. This study evalua... | Recovering | ReactionOutcome | CC BY | 34050660 | 19,407,420 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anaemia'. | Haemochromatosis in a kidney transplant recipient: a case report.
Iron overload is inevitably related to chronic kidney disease (CKD) treatment. Haemochromatosis leads to multiorgan damage and is associated with increased mortality. Primary haemochromatosis is the most common autosomal recessive disease in white popula... | MYCOPHENOLATE MOFETIL, PREDNISONE, TACROLIMUS | DrugsGivenReaction | CC BY | 34051741 | 19,974,256 | 2021-05-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cardiac failure'. | Haemochromatosis in a kidney transplant recipient: a case report.
Iron overload is inevitably related to chronic kidney disease (CKD) treatment. Haemochromatosis leads to multiorgan damage and is associated with increased mortality. Primary haemochromatosis is the most common autosomal recessive disease in white popula... | MYCOPHENOLATE MOFETIL, PREDNISONE, TACROLIMUS | DrugsGivenReaction | CC BY | 34051741 | 19,974,256 | 2021-05-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Glucose tolerance impaired'. | Haemochromatosis in a kidney transplant recipient: a case report.
Iron overload is inevitably related to chronic kidney disease (CKD) treatment. Haemochromatosis leads to multiorgan damage and is associated with increased mortality. Primary haemochromatosis is the most common autosomal recessive disease in white popula... | MYCOPHENOLATE MOFETIL, PREDNISONE, TACROLIMUS | DrugsGivenReaction | CC BY | 34051741 | 19,974,256 | 2021-05-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Liver injury'. | Haemochromatosis in a kidney transplant recipient: a case report.
Iron overload is inevitably related to chronic kidney disease (CKD) treatment. Haemochromatosis leads to multiorgan damage and is associated with increased mortality. Primary haemochromatosis is the most common autosomal recessive disease in white popula... | MYCOPHENOLATE MOFETIL, PREDNISONE, TACROLIMUS | DrugsGivenReaction | CC BY | 34051741 | 19,974,256 | 2021-05-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Urinary tract infection enterococcal'. | Haemochromatosis in a kidney transplant recipient: a case report.
Iron overload is inevitably related to chronic kidney disease (CKD) treatment. Haemochromatosis leads to multiorgan damage and is associated with increased mortality. Primary haemochromatosis is the most common autosomal recessive disease in white popula... | MYCOPHENOLATE MOFETIL, PREDNISONE, TACROLIMUS | DrugsGivenReaction | CC BY | 34051741 | 19,405,893 | 2021-05-29 |
What was the administration route of drug 'IRON'? | Haemochromatosis in a kidney transplant recipient: a case report.
Iron overload is inevitably related to chronic kidney disease (CKD) treatment. Haemochromatosis leads to multiorgan damage and is associated with increased mortality. Primary haemochromatosis is the most common autosomal recessive disease in white popula... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34051741 | 19,489,029 | 2021-05-29 |
What was the outcome of reaction 'Anaemia'? | Haemochromatosis in a kidney transplant recipient: a case report.
Iron overload is inevitably related to chronic kidney disease (CKD) treatment. Haemochromatosis leads to multiorgan damage and is associated with increased mortality. Primary haemochromatosis is the most common autosomal recessive disease in white popula... | Recovered | ReactionOutcome | CC BY | 34051741 | 19,974,256 | 2021-05-29 |
What was the outcome of reaction 'Cardiac failure'? | Haemochromatosis in a kidney transplant recipient: a case report.
Iron overload is inevitably related to chronic kidney disease (CKD) treatment. Haemochromatosis leads to multiorgan damage and is associated with increased mortality. Primary haemochromatosis is the most common autosomal recessive disease in white popula... | Recovered | ReactionOutcome | CC BY | 34051741 | 19,974,256 | 2021-05-29 |
What was the outcome of reaction 'Cytomegalovirus infection'? | Haemochromatosis in a kidney transplant recipient: a case report.
Iron overload is inevitably related to chronic kidney disease (CKD) treatment. Haemochromatosis leads to multiorgan damage and is associated with increased mortality. Primary haemochromatosis is the most common autosomal recessive disease in white popula... | Recovered | ReactionOutcome | CC BY | 34051741 | 19,439,406 | 2021-05-29 |
What was the outcome of reaction 'Enterococcal infection'? | Haemochromatosis in a kidney transplant recipient: a case report.
Iron overload is inevitably related to chronic kidney disease (CKD) treatment. Haemochromatosis leads to multiorgan damage and is associated with increased mortality. Primary haemochromatosis is the most common autosomal recessive disease in white popula... | Recovered | ReactionOutcome | CC BY | 34051741 | 19,439,406 | 2021-05-29 |
What was the outcome of reaction 'Glucose tolerance impaired'? | Haemochromatosis in a kidney transplant recipient: a case report.
Iron overload is inevitably related to chronic kidney disease (CKD) treatment. Haemochromatosis leads to multiorgan damage and is associated with increased mortality. Primary haemochromatosis is the most common autosomal recessive disease in white popula... | Recovered | ReactionOutcome | CC BY | 34051741 | 19,974,256 | 2021-05-29 |
What was the outcome of reaction 'Liver injury'? | Haemochromatosis in a kidney transplant recipient: a case report.
Iron overload is inevitably related to chronic kidney disease (CKD) treatment. Haemochromatosis leads to multiorgan damage and is associated with increased mortality. Primary haemochromatosis is the most common autosomal recessive disease in white popula... | Recovered | ReactionOutcome | CC BY | 34051741 | 19,974,256 | 2021-05-29 |
What was the outcome of reaction 'Transplant dysfunction'? | Haemochromatosis in a kidney transplant recipient: a case report.
Iron overload is inevitably related to chronic kidney disease (CKD) treatment. Haemochromatosis leads to multiorgan damage and is associated with increased mortality. Primary haemochromatosis is the most common autosomal recessive disease in white popula... | Recovered | ReactionOutcome | CC BY | 34051741 | 19,439,406 | 2021-05-29 |
What was the outcome of reaction 'Urinary tract infection'? | Haemochromatosis in a kidney transplant recipient: a case report.
Iron overload is inevitably related to chronic kidney disease (CKD) treatment. Haemochromatosis leads to multiorgan damage and is associated with increased mortality. Primary haemochromatosis is the most common autosomal recessive disease in white popula... | Recovered | ReactionOutcome | CC BY | 34051741 | 19,974,256 | 2021-05-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | A preliminary study on the characteristics of Th1/Th2 immune response in cerebrospinal fluid of AIDS patients with cryptococcal meningitis.
BACKGROUND
Cryptococcal Meningitis (CM) is a common opportunistic infection in the late stage of acquired immunodeficiency syndrome (AIDS). Despite the wide use of effective antire... | AMPHOTERICIN B, FLUCONAZOLE | DrugsGivenReaction | CC BY | 34051748 | 20,165,391 | 2021-05-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Intracranial pressure increased'. | A preliminary study on the characteristics of Th1/Th2 immune response in cerebrospinal fluid of AIDS patients with cryptococcal meningitis.
BACKGROUND
Cryptococcal Meningitis (CM) is a common opportunistic infection in the late stage of acquired immunodeficiency syndrome (AIDS). Despite the wide use of effective antire... | AMPHOTERICIN B, FLUCONAZOLE | DrugsGivenReaction | CC BY | 34051748 | 20,165,391 | 2021-05-29 |
What was the outcome of reaction 'Drug ineffective'? | A preliminary study on the characteristics of Th1/Th2 immune response in cerebrospinal fluid of AIDS patients with cryptococcal meningitis.
BACKGROUND
Cryptococcal Meningitis (CM) is a common opportunistic infection in the late stage of acquired immunodeficiency syndrome (AIDS). Despite the wide use of effective antire... | Fatal | ReactionOutcome | CC BY | 34051748 | 20,165,391 | 2021-05-29 |
What was the outcome of reaction 'Intracranial pressure increased'? | A preliminary study on the characteristics of Th1/Th2 immune response in cerebrospinal fluid of AIDS patients with cryptococcal meningitis.
BACKGROUND
Cryptococcal Meningitis (CM) is a common opportunistic infection in the late stage of acquired immunodeficiency syndrome (AIDS). Despite the wide use of effective antire... | Fatal | ReactionOutcome | CC BY | 34051748 | 20,165,391 | 2021-05-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lung disorder'. | Pulmonary Nocardia infection in a child with idiopathic pulmonary hemosiderosis.
BACKGROUND
Idiopathic pulmonary hemosiderosis (IPH) encompasses a rare and agnogenic group of diffuse alveolar capillary hemorrhagic diseases. Corticosteroid treatment is the globally preferred therapeutic strategy for IPH; however, it can... | METHYLPREDNISOLONE, SULBACTAM, VORICONAZOLE | DrugsGivenReaction | CC BY | 34051779 | 20,127,642 | 2021-05-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nocardiosis'. | Pulmonary Nocardia infection in a child with idiopathic pulmonary hemosiderosis.
BACKGROUND
Idiopathic pulmonary hemosiderosis (IPH) encompasses a rare and agnogenic group of diffuse alveolar capillary hemorrhagic diseases. Corticosteroid treatment is the globally preferred therapeutic strategy for IPH; however, it can... | METHYLPREDNISOLONE, VORICONAZOLE | DrugsGivenReaction | CC BY | 34051779 | 20,121,372 | 2021-05-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pleural thickening'. | Pulmonary Nocardia infection in a child with idiopathic pulmonary hemosiderosis.
BACKGROUND
Idiopathic pulmonary hemosiderosis (IPH) encompasses a rare and agnogenic group of diffuse alveolar capillary hemorrhagic diseases. Corticosteroid treatment is the globally preferred therapeutic strategy for IPH; however, it can... | METHYLPREDNISOLONE, SULBACTAM, VORICONAZOLE | DrugsGivenReaction | CC BY | 34051779 | 20,127,642 | 2021-05-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumonia bacterial'. | Pulmonary Nocardia infection in a child with idiopathic pulmonary hemosiderosis.
BACKGROUND
Idiopathic pulmonary hemosiderosis (IPH) encompasses a rare and agnogenic group of diffuse alveolar capillary hemorrhagic diseases. Corticosteroid treatment is the globally preferred therapeutic strategy for IPH; however, it can... | METHYLPREDNISOLONE, VORICONAZOLE | DrugsGivenReaction | CC BY | 34051779 | 20,121,372 | 2021-05-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pulmonary cavitation'. | Pulmonary Nocardia infection in a child with idiopathic pulmonary hemosiderosis.
BACKGROUND
Idiopathic pulmonary hemosiderosis (IPH) encompasses a rare and agnogenic group of diffuse alveolar capillary hemorrhagic diseases. Corticosteroid treatment is the globally preferred therapeutic strategy for IPH; however, it can... | METHYLPREDNISOLONE, SULBACTAM, VORICONAZOLE | DrugsGivenReaction | CC BY | 34051779 | 20,127,642 | 2021-05-29 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapy non-responder'. | Pulmonary Nocardia infection in a child with idiopathic pulmonary hemosiderosis.
BACKGROUND
Idiopathic pulmonary hemosiderosis (IPH) encompasses a rare and agnogenic group of diffuse alveolar capillary hemorrhagic diseases. Corticosteroid treatment is the globally preferred therapeutic strategy for IPH; however, it can... | METHYLPREDNISOLONE, SULBACTAM, VORICONAZOLE | DrugsGivenReaction | CC BY | 34051779 | 20,127,642 | 2021-05-29 |
What was the administration route of drug 'SULBACTAM'? | Pulmonary Nocardia infection in a child with idiopathic pulmonary hemosiderosis.
BACKGROUND
Idiopathic pulmonary hemosiderosis (IPH) encompasses a rare and agnogenic group of diffuse alveolar capillary hemorrhagic diseases. Corticosteroid treatment is the globally preferred therapeutic strategy for IPH; however, it can... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34051779 | 20,127,642 | 2021-05-29 |
What was the administration route of drug 'VORICONAZOLE'? | Pulmonary Nocardia infection in a child with idiopathic pulmonary hemosiderosis.
BACKGROUND
Idiopathic pulmonary hemosiderosis (IPH) encompasses a rare and agnogenic group of diffuse alveolar capillary hemorrhagic diseases. Corticosteroid treatment is the globally preferred therapeutic strategy for IPH; however, it can... | Oral | DrugAdministrationRoute | CC BY | 34051779 | 20,127,642 | 2021-05-29 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.